Dr. Rolfo on Precision Medicine in Lung Cancer

Christian Rolfo, MD, PhD
Published: Wednesday, Jan 11, 2017



Christian Diego Rolfo, MD, PhD, professor and unit coordinator at Antwerp University discusses the European perspective on precision medicine in lung cancer and the importance of clinical trials across different markets.

According to Rolfo, in a time where liquid biopsies and biomarkers are being developed for the treatment of patients with lung cancer, clinical trials are invaluable. Additionally, conferences such as IASLC are important in bridging communication between the various markets of development, specifically North American, European, and Asian.

Although competitors in the marketplace, Rolfo says that as a community, oncologists must be more proactive networkers and should develop a more positive attitude in working together across borders, as the only way to improve participation in clinical trials is to reach as many potential patients as possible.
 


Christian Diego Rolfo, MD, PhD, professor and unit coordinator at Antwerp University discusses the European perspective on precision medicine in lung cancer and the importance of clinical trials across different markets.

According to Rolfo, in a time where liquid biopsies and biomarkers are being developed for the treatment of patients with lung cancer, clinical trials are invaluable. Additionally, conferences such as IASLC are important in bridging communication between the various markets of development, specifically North American, European, and Asian.

Although competitors in the marketplace, Rolfo says that as a community, oncologists must be more proactive networkers and should develop a more positive attitude in working together across borders, as the only way to improve participation in clinical trials is to reach as many potential patients as possible.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x